Coronary Heart Disease (CHD) is the most deadly disease in the United States and the one whose risks are most modifiable by lifestyle measures. The rationale for CHD risk reduction is clear, well studied and outlined in this article. From aggressive assessment with a history and physical, basic laboratory studies, nutritional assessment and a physical activity assessment, CHD risks can be adequately quantified. The challenge now is in defining how to fully implement the effective strategies; both pharmacologic and nonpharmacologic (lifestyle) that have been proven to reduce the risks.
Mosca L, Linfante AH, Benjamin EJ, et al.National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111: 499-510.
2.
Mosca L, Mochari H, Christian C, et al.National Study of Women's Awareness, preventive action and barriers to cardiovascular health. Circulation. 2006;113: 525-534.
3.
Mosca L.Raising awareness of heart disease risk in women. JAMA. 2005;293: 1717-1717.
4.
Doran T, Fullwood C, Gravelle H, et al.Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med.2006;355: 375-384.
5.
Epstein AM.Paying for performance in the United States and abroad. N Engl J Med.2006;355: 406-408.
6.
Rosenthal MB, Frank RG, Li Z, Epstein AM.Early experience with pay-for-performance: from concept to practice. JAMA. 2005;294: 1788-1793.
7.
Rippe JM, Angelopoulos T, Zuckley L.The rationale for intervention to reduce coronary heart disease risk. Am J Lifestyle Med.2007;1: 1-10.
8.
Waters DD.What the statin trials have taught us. Am J Cardiol.2006;98: 129-134.
9.
Geiss LS, Pan L, Cadwell B, Gregg EW, Benjamin SM, Engelgau MM.Changes in incidence of diabetes in U.S. adults, 1997-2003. Am J Prev Med.2006;30: 371-377.
10.
Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM.Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295: 1549-1555.
11.
Grundy SM.Does the metabolic syndrome exist? Diabetes Care. 2006;29: 1689-1692.
12.
Grundy SM, Cleeman JI, Daniels SR, et al.Diagnosis and management of the metabolic syndrome: a statement for health care professionals. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112: 2735-2752.
13.
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med.2002;346: 393-403.
14.
Gluckman TJ, Baranowski B, Ashen MD, et al.A practical and evidence-based approach to cardiovascular disease risk reduction. Arch Intern Med.2004;164: 1490-1500.
Toth PP.High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol.2005;96(9A): 50-58.
17.
Whitney EJ, Krasuski RA, Personius BE, et al.A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med.2005;142: I46-I46.
18.
Sibley C, Blumenthal RS, Merz CN, Mosca L.Limitations of current cardiovascular disease risk assessment strategies in women. J Womens Health.2006;15: 54-56
19.
Duvernoy C, Martin JW, Briesmiester K, Muzk OO, Mosca L.Self-reported physical activity and myocardial flow reserve in postmenopausal women at risk for cardiovascular disease. J Womens Health.2006;15: 45-50.
20.
Mosca L, Edelman D, Mochari H, Christian AH, Paultre F, Pollin I.Waist circumference predicts cardiometabolic and global Framingham risk among women screened during National Woman's Heart Day. J Womens Health.2006;15: 24-34.
21.
Hecht HS, Budoff MJ, Berman DS, Ehrlich J, Rumberger JA.Coronary artery calcium scanning: clinical paradigms for cardiac risk assessment and treatment. Am Heart J.2006;151: 1139-1146.
22.
Mark DB, Lauer MS.Exercise capacity: the prognostic variable that doesn't get enough respect. Circulation. 2003;108: 1534-1536.
23.
Hambrecht R, Walther C, Mobius-Winkler S, et al.Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004;109: 1371-1378.
24.
Gulati M, Pandey DK, Arnsdorf MF, et al.Exercise capacity and the risk of death in women: the St. James Women Take Heart Project. Circulation. 2002;108: 1554-1559.
25.
de Lorgeril M, Salen P.The Mediterranean style diet for the prevention of cardiovascular diseases. Public Health Nutr.2006;9(1A): 118-123.
26.
Estruch R, Martinez-Gonzalez MA, Corella D, et al, for the PRIDIMED study investigators. Effects of a Mediterranean-style diet on cardiovascular risk factors. Ann Intern Med.2006;145: 1-11.
27.
Marchioli R, Schweiger C, Tavazzi L, Valagussa F.Efficacy of n-3 polyunsatu-rated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lipids. 2001;36(suppl): S119-S126.
28.
Bazzano LA, Serdula MK, Liu S.Dietary intake of fruits and vegetables and risk of cardiovascular disease. Curr Atheroscler Rep.2003;5: 492-499.
29.
Smith SC Jr, Allen J, Blair SN, et al.AHA/ACC, National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113: 2363-2372.
